Company
Headquarters: Hangzhou, China
Employees: 266
CEO: Dr. Jinzi Jason Wu
HK$14.50 Billion
HKD as of Jan. 1, 2026
US$1.86 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. It offers Ganovo, a protease inhibitor for the treatment of hepatitis C virus (HCV); Pegasys, an interferon receptor for the treatment of chronic Hepatitis B; and Ravidasvir, a NS5A inhibitor for the treatment of HCV. Its products pipeline includes ASC22, a PD-L1 single domain antibody fragment crystallizable fusion, which is in Phase II trial for the treatment of chronic Hepatitis B; ASC40, a fatty acid synthase inhibitor, which has completed Phase II clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); ASC41, a thyroid hormone receptor beta agonist, which has completed Phase Ib clinical trials for the treatment of NASH; and ASC42, a Farnesoid X Receptor agonist. The company's products also comprise ASC09, a protease inhibitor that has completed Phase IIa clinical trial to treat HIV; and ASC21, a NS5B polymerase inhibitor. In addition, it is developing therapies that are in pre-clinical trials for the treatment of Covid-19, hepatitis B virus, and NASH. The company was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.
| Last Financial Reports Date | June 30, 2018 |
| Revenue TTM | HK$2.6 M |
| EBITDA | HK$-453,925,821 |
| Gross Profit TTM | HK$951,854 |
| Profit Margin | 57.29% |
| Operating Margin | -17609.62% |
| Quarterly Revenue Growth | 25.46% |
Ascletis Pharma, Inc. has the following listings and related stock indices.
Stock: HKEX: 1672 wb_incandescent
Stock: FSX: 2VJ wb_incandescent
Stock: OTC: ASCLF wb_incandescent